For research use only. Not for therapeutic Use.
ABT-100（Cat No.:I000734）is a selective, orally bioavailable antagonist of the metabotropic glutamate receptor subtype 4 (mGluR4), which plays a role in modulating neurotransmission and is implicated in various neurological and psychiatric disorders. By targeting mGluR4, ABT-100 helps regulate glutamate signaling, showing potential in research for treating conditions such as Parkinson’s disease, anxiety, and pain. Its specificity for mGluR4 provides insights into glutamate’s role in the central nervous system, making ABT-100 valuable in exploring therapeutic approaches that involve precise modulation of neurotransmitter pathways in neurodegenerative and mood disorders.
| Catalog Number | I000734 |
| CAS Number | 450839-40-4 |
| Synonyms | ABT100; ABT 100; ABT-100; A367074; A 367074; A-367074;(S)-6-(2-(4-cyanophenyl)-2-hydroxy-2-(1-methyl-1H-imidazol-5-yl)ethoxy)-4/’-(trifluoromethoxy)-[1,1/’-biphenyl]-3-carbonitrile |
| Molecular Formula | C27H19F3N4O3 |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months). |
| IUPAC Name | 4-[(2S)-2-(4-cyanophenyl)-2-hydroxy-2-(3-methylimidazol-4-yl)ethoxy]-3-[4-(trifluoromethoxy)phenyl]benzonitrile |
| InChI | InChI=1S/C27H19F3N4O3/c1-34-17-33-15-25(34)26(35,21-7-2-18(13-31)3-8-21)16-36-24-11-4-19(14-32)12-23(24)20-5-9-22(10-6-20)37-27(28,29)30/h2-12,15,17,35H,16H2,1H3/t26-/m0/s1 |
| InChIKey | HEUVRFNVTLGKMZ-SANMLTNESA-N |
| SMILES | CN1C=NC=C1[C@](COC2=C(C=C(C=C2)C#N)C3=CC=C(C=C3)OC(F)(F)F)(C4=CC=C(C=C4)C#N)O |
| Reference | </br>1:A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies. Gu WZ, Joseph I, Wang YC, Frost D, Sullivan GM, Wang L, Lin NH, Cohen J, Stoll VS, Jakob CG, Muchmore SW, Harlan JE, Holzman T, Walten KA, Ladror US, Anderson MG, Kroeger P, Rodriguez LE, Jarvis KP, Ferguson D, Marsh K, Ng S, Rosenberg SH, Sham HL, Zhang H.Anticancer Drugs. 2005 Nov;16(10):1059-69. PMID: 16222147 </br>2:Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. Si MS, Ji P, Lee M, Kwok J, Kusumoto J, Naasz E, Ng SC, Imagawa DK.J Heart Lung Transplant. 2005 Sep;24(9):1403-9. PMID: 16143263 </br>3:Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. Carloni V, Vizzutti F, Pantaleo P.Clin Cancer Res. 2005 Jun 1;11(11):4266-74. PMID: 15930366 Free Article</br>4:Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O/’Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.Clin Cancer Res. 2005 Apr 15;11(8):3045-54. PMID: 15837760 Free Article |
